Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.51 |
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CTSV | O60911 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11381627 | 0.90 | IDO1 (0.58) | L3MBTL1TDP1MAPK1ALDH1A1CASP7 | |
| SCHEMBL15984934 | 0.89 | EGFR (0.55) | L3MBTL1TDP1MAPK1ALDH1A1CASP7 | |
| SCHEMBL1165347 | 0.87 | L3MBTL1 (0.65) | L3MBTL1TDP1MAPK1ALDH1A1CASP7 | |
| SCHEMBL30847370 | 0.87 | L3MBTL1 (0.65) | L3MBTL1TDP1MAPK1ALDH1A1CASP7 | |
| SCHEMBL3012215 | 0.84 | ALDH3A1 (0.61) | L3MBTL1TDP1MAPK1ALDH1A1CASP7 | |
| SCHEMBL11467953 | 0.84 | MAPT (0.63) | L3MBTL1TDP1MAPK1ALDH1A1HCAR3 | |
| SCHEMBL11389067 | 0.84 | L3MBTL1 (0.64) | L3MBTL1TDP1MAPK1ALDH1A1CASP7 | |
| SCHEMBL11554686 | 0.84 | L3MBTL1 (0.63) | L3MBTL1TDP1MAPK1ALDH1A1CASP7 | |
| SCHEMBL3323396 | 0.84 | MAPT (0.51) | L3MBTL1TDP1MAPK1ALDH1A1CASP7 | |
| SCHEMBL9950097 | 0.83 | HCAR3 (0.53) | L3MBTL1TDP1MAPK1ALDH1A1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11665961-B2 | Heterocyclic compound and organic light emitting device using same | LT MATERIALS CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
| CN-112830897-B | Ureido-containing benzimidazole derivative and preparation method and application thereof | 石家庄以岭药业股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2021098671-A1 | UREIDO-CONTAINING BENZIMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 石家庄以岭药业股份有限公司 | 2021-05-27 | — | — | WO | disclosed |
| CN-112830897-A | Ureido-containing benzimidazole derivative and preparation method and application thereof | 石家庄以岭药业股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-109516980-B | Bipolar material and organic light emitting diode element | 邱天隆 | 2020-12-11 | — | — | CN | disclosed |
| US-10825994-B2 | Organic light emitting device and preparation method thereof | Wuhan China Star Optoelectronics Technology, Ltd. (CN) | 2020-11-03 | — | — | US | disclosed |
| EP-2174932-B1 | Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-2174933-B1 | BENZIMIDAZOLE DERIVATIVES FOR USE IN ORGANIC ELECTROLUMINESCENT DEVICES | IDEMITSU KOSAN CO (JP) | 2019-04-03 | — | — | EP | disclosed |
| CN-109516980-A | Bipolar material and organic light emitting diode element | 邱天隆 | 2019-03-26 | — | — | CN | disclosed |
| US-20180331302-A1 | ORGANIC LIGHT EMITTING DEVICE AND PREPARATION METHOD THEREOF | WUHAN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-11-15 | — | — | US | disclosed |
| US-20070200490-A1 | Nitrogenous Heterocycle Derivative, And Organic Electroluminescent Element Employing The Same | IDEMITSU KASON CO.LTD (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070138950-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070138950-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| WO-2007061737-A2 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1734038-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20060147747-A1 | 2-[4-(10-naphthalene-2-yl-anthracene-9-yl)-phenyl]-1-phenyl-1H-benzimidazole; elevation of luminance and of efficiency in light emission even under low driving voltage | IDEMITSU KOSAN CO., LTD. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1602648-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10825994-B2 | Organic light emitting device and preparation method thereof | CYBA, CYP1A2, CYP2B6 | L3MBTL1 1292/4885TDP1 2831/4885MAPK1 1928/4885 |
| US-20070200490-A1 | Nitrogenous Heterocycle Derivative, And Organic Electroluminescent Element Employing The Same | RPS3A, NCOA3, HNRNPA0 | L3MBTL1 816/4885TDP1 2403/4885MAPK1 1144/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | L3MBTL1 3706/4885TDP1 4000/4885MAPK1 40/4885 |
| US-20180331302-A1 | ORGANIC LIGHT EMITTING DEVICE AND PREPARATION METHOD THEREOF | CYBA, CYP1A2, CYP2B6 | L3MBTL1 1292/4885TDP1 2831/4885MAPK1 1928/4885 |
| US-11665961-B2 | Heterocyclic compound and organic light emitting device using same | CRY1, CYP1B1, CRY2 | L3MBTL1 1649/4885TDP1 2218/4885MAPK1 751/4885 |
| US-20070138950-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | EHD1, HCN2, ODC1 | L3MBTL1 1547/4885TDP1 1246/4885MAPK1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.